RF microneedling device gains regulatory clearance in mainland China, signaling expansion beyond U.S. and Europe.
Sofwave has received NMPA (National Medical Products Administration) approval in mainland China, clearing the path for commercial distribution of its radiofrequency microneedling platform. The device combines fractional RF energy with microneedling depth to induce collagen remodeling—a mechanism that resonates in Asian markets where skin tightening and texture refinement command premium pricing.
China's aesthetic device market has consolidated around a handful of players, but RF microneedling remains a growth category. Sofwave's entry competes directly against InMode's Morpheus8 and Cutera's Cutera Xeo RF offerings already operating there. The approval removes regulatory friction and lets Sofwave build channel partnerships with major Chinese aesthetic chains and hospital systems.
NMPA approval opens China's RF microneedling market for Sofwave.
For U.S. practices: this signals Sofwave's capital strength and global ambitions. A company expanding aggressively into regulated international markets is investing in R&D and manufacturing durability.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
